Original Contribution
The American Journal of Gastroenterology (2007) 102, 814–819; doi:10.1111/j.1572-0241.2007.01055.x
Long-Term Outcome of Crohn's Disease Following Corticosteroid-Induced Remission
Claudio Papi MD1, Virginia Festa MD1, Gioacchino Leandro MD2, Alessandra Moretti MD1, Monica Tanga MD1, Maurizio Koch MD1 and Lucio Capurso MD1
- 1Gastroenterology Unit, S. Filippo Neri Hospital, Rome, Italy
- 2Gastroenterology Unit, IRCCS De Bellis, Castellana Grotte (Bari), Bari, Italy
Correspondence: Claudio Papi, MD, UOC Gastroenterologia, Ospedale S. Filippo Neri, Via Martinotti 20, 00135 Roma, Italy.
Received 19 August 2006; Accepted 1 November 2006.
Abstract
INTRODUCTION:
Corticosteroids are the gold standard in the treatment of moderate to severe Crohn's disease but are often associated with severe and potentially dangerous side effects. Despite an initial clinical response many patients become steroid dependent or require further steroid courses in the long term. The aim of the present study was to assess the probability of the need for further steroid treatment in Crohn's disease patients following steroid-induced remission and to establish if clinical variables can predict further steroid needs.
PATIENTS AND METHODS:
All patients at their first steroid course and with corticosteroid-induced remission, defined as a Crohn's Disease Activity Index (CDAI) <150, 4 wk after steroid weaning, were studied and observed at follow-up for 12 months. The main outcome was clinical relapse requiring further steroid treatment. Statistical analysis was performed using the Kaplan-Meier method and multivariable Cox proportional hazard regression model taking into consideration gender, age at diagnosis, disease location and behavior, smoking habits, CDAI score before steroid treatment, and C reactive protein values at steroid weaning, as covariates.
RESULTS:
A total of 77 patients with steroid-induced remission were included. One-year follow-up was available in 75 of the 77 patients (97.4%). During follow-up 49 of 75 patients (65.3%) maintained remission or presented mild relapse not requiring steroids while 26 of 75 patients (34.6%) had moderate to severe relapse requiring further steroid treatment. The cumulative probability of a course free from steroids was 93.3%, 82.6%, 78.6%, and 66.6% at 3, 6, 9, and 12 months, respectively. At multivariate analysis, increased C reactive protein at steroid weaning and penetrating complications were independent risk factors for further steroid requirement (OR 5.57, 95% CI 1.20–25.91, P = 0.001 and OR 4.20, 95% CI 1.76–10.04, P = 0.005, respectively).
CONCLUSION:
Despite an initial clinical response and successful steroid tapering, 35% of patients required further steroid treatment within 1 yr. An increased C reactive protein value, at steroid weaning, despite clinical remission, and penetrating complications may predict further steroid requirement in already steroid responsive patients.
